Certificates of supplementary protection : one year later
CERTIFICATESOFSUPPLEMENTARYPROTECTION:ONEYEARLATER
DANIÈLEÉTHIERANDAMÉLIECÔTÉ*
ROBIC,LLP
LAWYERS,PATENTANDTRADEMARKAGENTS
SinceSeptember21,2017,anewCertificateofSupplementaryProtection(hereafterreferredto
asa”CSP”)Regimehasbeenimplementedwhichmayallowpatentholderstoreceiveupto2
yearsofadditionalpatentprotectionforapprovedmedicines.Inthepastyear,severalCSP
applicationshavebeensubmittedandreviewed,whichgivesusinsightastohowthisadditional
protectionisgrantedandhowtheCSPregulationsareinterpretedbyHealthCanada.
THECSPSCHEMEANDELIGIBILITY
TheCSPregimewasimplementedtocompensatepatentholdersfortimespentinresearchand
developmentfordrugscontainingpatentedmedicinalingredients.ACSPmayallowapatentholder
tobenefitfromuptotwoadditionalyearsofpatentprotectionontheapprovedmedicinalingredient
orcombinationofmedicinalingredients.
OnceaCanadianpatentisgranted,apatentholderormanufacturercanapplyforaCSPifallof
thefollowingconditionsaremet:
•ThepatentisinforceandisbasedonanapplicationwhichwasfiledinCanadaafterOctober
1,1989†;
•Thepatentrelatestothesamemedicinalingredientoracombinationofthesamemedicinal
ingredientscontainedinamedicineforhumanorveterinaryuse‡;
•Thefirstmarketingauthorization(i.e.noticeofcompliance)forthemedicinalingredientora
combinationwasissuedafterSeptember21,2017§;
•TheapplicationformarketauthorizationwasfiledinCanadawithin1year(or2yearsforthe
firstyearofapplicationoftheCSPscheme)afterthedateonwhichthefirstequivalent
applicationwassubmittedinacountryoftheEuropeanUnion,theUnitedStates,Australia,
SwitzerlandorJapan;
•NootherCSPhasbeengrantedforthemedicinalingredientoracombinationofthesame
medicinalingredients**;
©CIPS,2018.
*DanièleEthierisapartner,biochemistandCanadianpatentagentandAmélieCôtéisanarticlingstudent
workingatROBIC,LLP,afirmoflawyers,patentandtrademarkagents.†PatentAct,RSC1985,cP-4,s.106(1)a)andb);CertificateofSupplementaryProtectionRegulations,SOR/2017-165,s.3(1).‡CertificateofSupplementaryProtectionRegulations,SOR/2017-165,s.3(2).§PatentAct,RSC1985,cP-4,s.106(1)c.**Id.,s.106(1)e).
2
•Theapplicableregulatorytaxesarepaid;and
•TheCSPApplicationisfiledwithHealthCanadawithin120daysfromthelaterof(i)thefirst
marketauthorizationofthemedicinalproduct;or(ii)thegrantofthepatent††.
Aswillbeseenbelow,failuretomeetanyoneoftheconditionsabovemayresultintheCSP
applicationbeingrefused.
SUMMARYOFPASTAPPLICATIONS
HealthCanadamaintainsaRegisterwhichincludesinformationfromCSPsandCSPapplications.
AsofOctober26,2018,twenty-sixCSPapplicationswerefiled,fifteenCSPsweregrantedand
threeapplicationshavebeenrejected.
CSPapplication900001wasthefirstCSPapplicationfiledandwasrejectedbecausethemarket
approvalwasissuedpriortoSeptember21,2017.Therefore,theconditionsofsection106(1)cof
thePatentActwerenotmet.
BasedontheinformationprovidedbyHealthCanada,CSPapplication900011wasrejected
becausethemarketauthorizationforthedrugwasnotthefirstmarketingapprovalasrequiredby
thePatentActandtheCertificateofSupplementaryProtectionRegulations.Apriorapprovalwas
issuedforaprescribedvariationofthemedicinalingredient.Inthiscase,thevariationwasapost-
translationmodificationofthemedicinalingredient(pegylationand/orglycosylation).
CSPapplication900006withrespecttothedrugSHINGRIX®wasrejectedbecausetheclaimsof
thepatentdidnotcontainaneligiblepatentclaim.Theclaimsinthepatentinquestionaredirected
totheuseofacompositioncomprisingagEantigenandaselectedadjuvanttomakeavaccine.
Accordingtothecourtdocuments,theCSPapplicationwasrejectedonthegroundsthattheclaims
aredirectedtoaformulationcomprisingmedicinalandnon-medicinalingredients.Accordingtothe
CSPRegulations,onlypatentcontainingclaimsforthemedicinalingredients,combinationsofthe
medicinalingredient,usesandprocessesformakingsameareeligibleforaCSP‡‡.
TheApplicantforCSPApplicationNumber900006recentlyappliedforajudicialreviewoftheir
refusedapplication§§.TheApplicantessentiallyclaimsthattheMinistermisinterpretedtheCSP
regimeinfindingthatadjuvantsarenotmedicinalingredients***.Thedeterminationofthecourthas
yettobemade.Nonetheless,beingthefirstreviewofadecisionmadebytheHealthCanada
underthesenewregulations,thedecisionwillhopefullyclarifytheextentandlimitsofthisnewCSP
regime.
IMPORTANCEOFFULFILLINGTHECONDITIONS
CSPsallowpatentholderstobenefitfromanadditionalprotectionfortheirpatenteddrugs.To
benefitfromthisrecentregime,itishowevercrucialthattheCSPApplicationfulfillallofthe
††Id.,s.106(3);CertificateofSupplementaryProtectionRegulations,SOR/2017-165,s.6(2).‡‡SeeFederalCourtNoticeofApplicationNo.T-1603-18:https://www.robic.ca/publications/federal-court-glaxosmithkline-biological-s-minister-health/§§Id.***Id.,para.34.
3
conditionssetoutinthePatentActandtheCertificateofSupplementaryProtectionRegulations.
Ascanbeseenfromthecasesdiscussedabove,failingtoproperlyensurethatalltheeligibility
conditionsaremetmayresultintherefusaloftheCSPapplication.Ourteamofexpertscanhelp
youstrategicallycoordinateyourpatentsandCSPapplications,allwhileensuringthatregulatory
measuresaremet.Weinviteyoutocontactusforadditionalinformation.